89bio price target lowered to $30 from $31 at BofA

BofA lowered the firm’s price target on 89bio (ETNB) to $30 from $31 and keeps a Buy rating on the shares. While there weren’t many new updates in the company’s Q1 update, 89bio reiterated that key readouts in MASH and SHTG remain on track, says the analyst, who argues that the earnings release was “largely incremental” and continues to see “compelling upside potential for the stock.” The firm lowered its target after updating operating expense forecasts, the analyst noted.